Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma

Lawrence E. Harrison, Baburao Koneru, Phil Baramipour, Adrian Fisher, Alison Barone, Dorian Wilson, Andrew Dela Torre, Kyunghee C. Cho, Daniel Contractor, Maria Korogodsky

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

BACKGROUND: Enthusiasm for radiofrequency ablation (RFA) therapy for patients with unresectable hepatocellular carcinoma (HCC) has increased. The data for recurrence after RFA for patients with HCC is not well documented. The purpose of this study was to evaluate tumor recurrence patterns after RFA in patients with unresectable HCC. STUDY DESIGN: Over a 3-year period, 50 patients having RFA for unresectable HCC were identified at a single institution. Medical records and radiologic studies were reviewed and outcomes factors analyzed. RESULTS: Of the entire cohort, 46 patients underwent RFA by a percutaneous approach under CT guidance. Most patients underwent either one (n = 22) or two ablations (n = 23). At the time of this report, 14 patients (28%) were tumor-free by radiologic and biochemical (alpha-fetoprotein) parameters. Eighteen additional patients had persistence of tumor at the ablation site and 14 patients had recurrence in the liver at sites different from the ablation site. An additional four patients had recurrence in extrahepatic sites. Twelve patients underwent orthotopic liver transplantation after RFA. Of these 12, 5 (42%) demonstrated no viable tumor in the explanted liver. Independent predictors of tumor recurrence included tumor size, serum AFP levels, and the presence of hepatitis. CONCLUSIONS: These data suggest that factors such as tumor size should be considered before employing RFA therapy. In addition to treating the primary tumor, other therapies aimed at the liver's inflammatory state might also be important in achieving a durable response after RFA.

Original languageEnglish (US)
Pages (from-to)759-764
Number of pages6
JournalJournal of the American College of Surgeons
Volume197
Issue number5
DOIs
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Recurrence
Neoplasms
Liver
alpha-Fetoproteins
Liver Transplantation
Hepatitis
Medical Records
Therapeutics
Serum

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Harrison, Lawrence E. ; Koneru, Baburao ; Baramipour, Phil ; Fisher, Adrian ; Barone, Alison ; Wilson, Dorian ; Dela Torre, Andrew ; Cho, Kyunghee C. ; Contractor, Daniel ; Korogodsky, Maria. / Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. In: Journal of the American College of Surgeons. 2003 ; Vol. 197, No. 5. pp. 759-764.
@article{84fde12dfed344899d7a320b06342da8,
title = "Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma",
abstract = "BACKGROUND: Enthusiasm for radiofrequency ablation (RFA) therapy for patients with unresectable hepatocellular carcinoma (HCC) has increased. The data for recurrence after RFA for patients with HCC is not well documented. The purpose of this study was to evaluate tumor recurrence patterns after RFA in patients with unresectable HCC. STUDY DESIGN: Over a 3-year period, 50 patients having RFA for unresectable HCC were identified at a single institution. Medical records and radiologic studies were reviewed and outcomes factors analyzed. RESULTS: Of the entire cohort, 46 patients underwent RFA by a percutaneous approach under CT guidance. Most patients underwent either one (n = 22) or two ablations (n = 23). At the time of this report, 14 patients (28{\%}) were tumor-free by radiologic and biochemical (alpha-fetoprotein) parameters. Eighteen additional patients had persistence of tumor at the ablation site and 14 patients had recurrence in the liver at sites different from the ablation site. An additional four patients had recurrence in extrahepatic sites. Twelve patients underwent orthotopic liver transplantation after RFA. Of these 12, 5 (42{\%}) demonstrated no viable tumor in the explanted liver. Independent predictors of tumor recurrence included tumor size, serum AFP levels, and the presence of hepatitis. CONCLUSIONS: These data suggest that factors such as tumor size should be considered before employing RFA therapy. In addition to treating the primary tumor, other therapies aimed at the liver's inflammatory state might also be important in achieving a durable response after RFA.",
author = "Harrison, {Lawrence E.} and Baburao Koneru and Phil Baramipour and Adrian Fisher and Alison Barone and Dorian Wilson and {Dela Torre}, Andrew and Cho, {Kyunghee C.} and Daniel Contractor and Maria Korogodsky",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/S1072-7515(03)00750-6",
language = "English (US)",
volume = "197",
pages = "759--764",
journal = "Journal of the American College of Surgeons",
issn = "1072-7515",
publisher = "Elsevier Inc.",
number = "5",

}

Harrison, LE, Koneru, B, Baramipour, P, Fisher, A, Barone, A, Wilson, D, Dela Torre, A, Cho, KC, Contractor, D & Korogodsky, M 2003, 'Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma', Journal of the American College of Surgeons, vol. 197, no. 5, pp. 759-764. https://doi.org/10.1016/S1072-7515(03)00750-6

Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. / Harrison, Lawrence E.; Koneru, Baburao; Baramipour, Phil; Fisher, Adrian; Barone, Alison; Wilson, Dorian; Dela Torre, Andrew; Cho, Kyunghee C.; Contractor, Daniel; Korogodsky, Maria.

In: Journal of the American College of Surgeons, Vol. 197, No. 5, 01.01.2003, p. 759-764.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma

AU - Harrison, Lawrence E.

AU - Koneru, Baburao

AU - Baramipour, Phil

AU - Fisher, Adrian

AU - Barone, Alison

AU - Wilson, Dorian

AU - Dela Torre, Andrew

AU - Cho, Kyunghee C.

AU - Contractor, Daniel

AU - Korogodsky, Maria

PY - 2003/1/1

Y1 - 2003/1/1

N2 - BACKGROUND: Enthusiasm for radiofrequency ablation (RFA) therapy for patients with unresectable hepatocellular carcinoma (HCC) has increased. The data for recurrence after RFA for patients with HCC is not well documented. The purpose of this study was to evaluate tumor recurrence patterns after RFA in patients with unresectable HCC. STUDY DESIGN: Over a 3-year period, 50 patients having RFA for unresectable HCC were identified at a single institution. Medical records and radiologic studies were reviewed and outcomes factors analyzed. RESULTS: Of the entire cohort, 46 patients underwent RFA by a percutaneous approach under CT guidance. Most patients underwent either one (n = 22) or two ablations (n = 23). At the time of this report, 14 patients (28%) were tumor-free by radiologic and biochemical (alpha-fetoprotein) parameters. Eighteen additional patients had persistence of tumor at the ablation site and 14 patients had recurrence in the liver at sites different from the ablation site. An additional four patients had recurrence in extrahepatic sites. Twelve patients underwent orthotopic liver transplantation after RFA. Of these 12, 5 (42%) demonstrated no viable tumor in the explanted liver. Independent predictors of tumor recurrence included tumor size, serum AFP levels, and the presence of hepatitis. CONCLUSIONS: These data suggest that factors such as tumor size should be considered before employing RFA therapy. In addition to treating the primary tumor, other therapies aimed at the liver's inflammatory state might also be important in achieving a durable response after RFA.

AB - BACKGROUND: Enthusiasm for radiofrequency ablation (RFA) therapy for patients with unresectable hepatocellular carcinoma (HCC) has increased. The data for recurrence after RFA for patients with HCC is not well documented. The purpose of this study was to evaluate tumor recurrence patterns after RFA in patients with unresectable HCC. STUDY DESIGN: Over a 3-year period, 50 patients having RFA for unresectable HCC were identified at a single institution. Medical records and radiologic studies were reviewed and outcomes factors analyzed. RESULTS: Of the entire cohort, 46 patients underwent RFA by a percutaneous approach under CT guidance. Most patients underwent either one (n = 22) or two ablations (n = 23). At the time of this report, 14 patients (28%) were tumor-free by radiologic and biochemical (alpha-fetoprotein) parameters. Eighteen additional patients had persistence of tumor at the ablation site and 14 patients had recurrence in the liver at sites different from the ablation site. An additional four patients had recurrence in extrahepatic sites. Twelve patients underwent orthotopic liver transplantation after RFA. Of these 12, 5 (42%) demonstrated no viable tumor in the explanted liver. Independent predictors of tumor recurrence included tumor size, serum AFP levels, and the presence of hepatitis. CONCLUSIONS: These data suggest that factors such as tumor size should be considered before employing RFA therapy. In addition to treating the primary tumor, other therapies aimed at the liver's inflammatory state might also be important in achieving a durable response after RFA.

UR - http://www.scopus.com/inward/record.url?scp=0642280379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0642280379&partnerID=8YFLogxK

U2 - 10.1016/S1072-7515(03)00750-6

DO - 10.1016/S1072-7515(03)00750-6

M3 - Article

C2 - 14585410

AN - SCOPUS:0642280379

VL - 197

SP - 759

EP - 764

JO - Journal of the American College of Surgeons

JF - Journal of the American College of Surgeons

SN - 1072-7515

IS - 5

ER -